MedTrace Logo

Administration of Anti-SARS-CoV-2 Convalescent Plasma in Hospitalized, Non-ICU Patients With COVID-19

NCT04467151 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-10-22

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of the administration of anti-SARS-CoV-2 convalescent plasma in COVID-19 patients who are sick enough to warrant hospitalization, but not yet admitted to the ICU (prior to the onset of overwhelming disease including a systemic inflammatory response, sepsis, and/or ARDS).

Conditions

Interventions

DRUG

anti-SARS-CoV-2 plasma

Administration of anti-SARS-CoV-2 convalescent plasma

OTHER

Placebo

Administration of placebo (albumin 5%)

Sponsors & Collaborators

  • Kashif Khan

    lead OTHER

Principal Investigators

  • Kashif T Khan, MD, SM · Keck School of Medicine of University of Southern California

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-31
Primary Completion
2021-10-31
Completion
2021-12-31
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04467151 on ClinicalTrials.gov